Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | GRM6 | O15303 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31006018 | 0.85 | ELANE (0.41) | ELANECA2CA12CA1CA9 | |
| SCHEMBL18857950 | 0.85 | ELANE (0.41) | ELANECA2CA12CA1CA9 | |
| SCHEMBL17286509 | 0.84 | ESR1 (0.41) | ELANE | |
| SCHEMBL31617775 | 0.84 | ELANE (0.40) | ELANECA2CA12CA1CA9 | |
| SCHEMBL18857953 | 0.84 | ELANE (0.40) | ELANECA2CA12CA1CA9 | |
| SCHEMBL23413671 | 0.83 | NOTUM (0.40) | ELANECA2CA12CA1CA9 | |
| SCHEMBL18857933 | 0.83 | ELANE (0.39) | ELANECA2CA12CA1CA9 | |
| SCHEMBL18675818 | 0.83 | MTNR1A (0.39) | ELANECA2CA12CA1CA9 | |
| SCHEMBL23413776 | 0.81 | ELANE (0.37) | ELANECA2CA12CA1CA9 | |
| SCHEMBL15867220 | 0.81 | ELANE (0.37) | ELANECA2GRM6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230114728-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2023-04-13 | — | — | US | disclosed |
| WO-2021108023-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230114728-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | ELANE 44/4885CA2 2155/4885CA12 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.